Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead
Why it matters
A study found that 50% of patients who use GLP-1 injections (Wegovy and Zepbound) regain weight after stopping treatment, leading some to explore alternative weight-loss methods.
Article tone
Neutral
How the article is written, as reported by the source.
Expected market reaction
Market impact analysis based on bearish sentiment with 70% confidence.
Evidence trail
Evidence
Source
MarketWatch
Claim
Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead
AI inference
Bearish · 70%
Generated
2026-01-15 16:51
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 33190
Original source
New research has found that 50% of patients regain the weight they lost if they stop taking Wegovy and Zepbound
Read the full article on MarketWatch
Original article published by MarketWatch on January 15, 2026. Analysis and insights provided by AnalystMarkets AI.